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PEndothelial Progenitor Cells
Circulating Progenitor Cells Can Be Reliably Identified
on the Basis of Aldehyde Dehydrogenase Activity
Thomas J. Povsic, MD, PHD,* Katherine L. Zavodni, BS,* Francine L. Kelly, BS,*
Shoukang Zhu, PHD,* Pascal J. Goldschmidt-Clermont, MD, FACC,‡ Chunming Dong, MD,*
Eric D. Peterson, MD, MPH, FACC†
Durham, North Carolina; and Miami, Florida
Objectives Our objective was to develop and assess a novel endogenous progenitor cell (EPC) assay based on aldehyde de-
hydrogenase (ALDH) activity, and to define the relationship of ALDH-bright (ALDHbr) cells with previously defined
EPCs, patient age, and extent of coronary artery disease.
Background Accurate assessment of circulating EPCs is of significant interest, yet current assays have limitations. Progenitor cells
display high levels of ALDH activity. An assay based on ALDH activity may offer a simple means for enumerating EPCs.
Methods We simultaneously determined the numbers of EPCs based on ALDH activity and cell surface expression of
CD133, CD34, and vascular endothelial growth factor receptor-2 in 110 patients undergoing cardiac catheteriza-
tion. We assessed the reproducibility of these estimates, correlation among EPC assays, and the association of
ALDHbr numbers with age and disease severity.
Results Aldehyde dehydrogenase-bright cells were easily identified in nonmobilized peripheral blood with median and mean
frequencies of 0.041% and 0.074%, respectively. Aldehyde dehydrogenase-bright cells expressed CD34 or CD133 cell
surface markers (57.0% and 27.1%, respectively), correlated closely with CD133CD34 cells (r  0.72; p  0.001),
and differentiated into endothelial cells with greater efficiency than CD133CD34 cells. Aldehyde dehydrogenase-
bright cell numbers were inversely associated with patient age and coronary disease severity.
Conclusions Aldehyde dehydrogenase activity represents a novel simplified method for quantifying EPCs. The correlation of
ALDHbr cells with clinical factors and outcomes warrants further study. (J Am Coll Cardiol 2007;50:2243–8)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.033i
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Phe discovery of circulating endogenous progenitor cells
EPCs) capable of vascular repair (1) has broadened our
onception of atherosclerosis pathophysiology and treat-
ent (2). Most studies have found an inverse correlation
etween EPC number and cardiac risk factors (3,4), disease
everity (5), and risk for future cardiovascular events (6,7),
lthough these findings are not universal (8,9). This body of
ork suggests that accurate EPC enumeration may be
linically useful for assessment of vascular reparative capac-
ty and patient risk stratification; however, EPC enumera-
ion currently requires prompt cell culture or fluorescence-
ctivated cell sorting (FACS) analysis.
rom the *Division of Cardiology and †Duke Clinical Research Institute, Duke
niversity Medical Center, Durham, North Carolina; and the ‡Miller School of
edicine, University of Miami, Miami, Florida. Supported in part by National Heart,
ung, and Blood Institute grant K-18 HL081419-01A1, grants from the Duke
linical Research Institute, a Society of Geriatric Cardiology Merck Geriatric
ardiology Research Award, and Medtronic, through the Medtronic-Duke Strategic
lliance. Aldecount kits were provided by Aldagen, Durham, North Carolina.t
Manuscript received April 9, 2007; revised manuscript received August 23, 2007,
ccepted August 27, 2007.Cytosolic aldehyde dehydrogenase (ALDH) has been
dentified as the enzymatic activity responsible for the resis-
ance of progenitor cells to chemotherapeutic agents (10) and
an be used to select for a highly enriched population of
rogenitor cells in bone marrow (11,12) and umbilical cord
13) sources. In addition, ALDH activity is present at high
evels in progenitor precursors of a variety of mature cell
ines (14–16) and may play an important role in maintain-
ng the progenitor cell phenotype (17).
Recently, reagents for the dependable enumeration of
ldehyde dehydrogenase-bright (ALDHbr) cells in bone
arrow and mobilized blood using conventional FACS
echniques and requiring only a single color channel have
ecome available. We explored whether or not ALDH
ctivity could be used as a novel and simpler tool to assess
irculating EPC numbers in peripheral blood.
ethods
atient enrollment and mononuclear cell isolation. Pa-
ients undergoing elective left heart catheterization were ap-
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Identification of EPCs Based on ALDH Activity December 4, 2007:2243–8proached for consent, and after
arterial sheath insertion 30-ml pe-
ripheral blood was removed and
stored in ethylenediaminetetra-
acetic acid tubes. Arterial blood
was subjected to centrifugation
(2,000 g  10 min), and the buffy
coat was treated with 10 volumes
of erythrocyte lysis buffer (Alda-
gen, Durham, North Carolina).
The mononuclear cells (MNCs)
were isolated by centrifugation
(250 g  5 min), washed with
phosphate-buffered saline-1% bo-
vine serum albumin (Invitrogen,
Carlsbad, California), and ali-
quoted for analysis.
numeration of ALDHbr cells. Mononuclear cells (2 
06) were aliquoted to an Aldecount tube (Aldagen Inc.,
urham, North Carolina), incubated with BODIPY-AAD
t 37°C for 30 min, and maintained on ice to retain the
uorescent byproduct. A control reaction was performed in
he presence of diethylaminobenzaldehyde. Cells were spun
t 250 g  5 min, the reaction buffer removed, and the cells
uspended in assay buffer on ice until FACS analysis was
erformed.
nalysis of EPCs based on cell surface marker expression.
ononuclear cells (4  106 cells) were aliquoted, incubated
ith Fc receptor (FcR) blocking reagent (Miltenyi Biotec,
uburn, California) for 10 min, and incubated with
D133-APC (Miltenyi Biotec), CD34-FITC (Miltenyi
iotec), and VEGFR-2-PE (R&D Systems, Minneapolis,
innesota) for 60 min at 4°C. Dead and dying cells were
xcluded using staining with 7-AAD (1 g/106 cells;
nvitrogen). Directly conjugated isotype control antibodies
ere used to set baseline fluorescence levels.
ACS analysis. Flow cytometry was performed by trained
echnicians blinded to patient identity using an LSR II flow
ytometer (BD Biosciences, San Jose, California) and ana-
yzed using FlowJo software (Treestar, Costa Mesa, Cali-
ornia). Compensation was performed daily using BD
ompBeads incubated with each antibody.
Analysis was performed by gating lymphocytes and
onocytes on the basis of light-scattering properties. The
PCs were expressed as a percentage of this monocyte/
ymphocyte gate.
xpansion of ALDHbr cells into endothelial cells. Bone
arrow was purchased from Cambrex (Walkersville, Mary-
and), depleted of erythrocytes using erythrocyte lysis buffer,
abeled with Aldefluor reagent according to the manufac-
urer’s directions, and sorted on a modified FACS-ARIA
ell sorter (BD Biosciences) at 4°C.
The CD133/CD34 selection was performed using
D133-MACS beads (Miltenyi Biochemical). After elu-
ion from the beads, cells were incubated with PE- conju-
Abbreviations
and Acronyms
ALDH  aldehyde
dehydrogenase
ALDHbr  aldehyde
dehydrogenase-bright
CAD  coronary artery
disease
EPC  endogenous
progenitor cell
FACS  fluorescence-
activated cell sorting
MNC  mononuclear cell
VEGFR  vascular
endothelial growth
factor receptorated anti-CD34 and sorted on a modified FACS-ARIA pell sorter. The EPCs (5,000) were plated into fibronectin-
oated 4-well chamber slides (BD Biosciences) and incu-
ated in M199 medium containing 20% fetal calf serum, 10
g/ml recombinant human vascular endothelial growth
actor, 1 ng/ml b-fibroblast growth factor, and 2 ng/ml
nsulin-like growth factor 1. The numbers of adherent
lliptical endothelial cells were quantitated after 5 days. The
verages of 10 experiments are shown.
uke Cardiovascular Databank. The methods of the
uke Cardiovascular Databank have been previously de-
cribed (18,19). In brief, all patients who have undergone
ardiac catheterization, percutaneous coronary intervention,
r cardiac surgery have had their demographic, clinical,
ngiographic, and procedural data entered into a standard
atabase. All cardiac catheterization procedures are system-
tically reviewed in a standardized fashion by 2 operators.
oronary disease severity was summarized as number of
iseased coronary vessels, defined by at least 1 narrowing
75%.
tatistical analysis. The median and mean numbers (with
tandard deviations [SD]) of EPCs determined using each
ssay are reported, as are the mean numbers (SD) of
LDHbr cells expressing specific cell surface markers. A
earson correlation coefficient between independent EPC
ssessments was determined to assess the precision and
emporal stability of EPC assays. To compare these corre-
ations, the absolute difference between each matched pair
f determinations was calculated and these differences
ompared using a Mann-Whitney test.
A D’Agostino and Pearson omnibus normality test was
sed to determine the normality of each distribution. Given
on-normal distributions, Spearman correlations are re-
orted for associations between EPC types as well as the
ssociation of ALDHbr cells with age. Analysis of variance
nd analysis for linear trend were performed to assess
ssociation of ALDHbr cells with extent of coronary artery
isease (CAD).
GraphPad Prism 4.0 (GraftPad Software, San Diego,
alifornia) was used for all analyses.
esults
LDH assay and characterization of ALDHbr cells.
nalysis of ALDH activity was readily performed and
esulted in the straightforward identification of cells char-
cterized by high levels of ALDH activity and low side-
catter (Fig. 1). This population is not observed in the
resence of diethylaminobenzaldehyde, a potent inhibitor of
LDH.
We characterized ALDHbr cells by counterstaining for
D133, CD34, and vascular endothelial growth factor
eceptor (VEGFR)-2 expression in 21 patients. As shown in
igure 2, 57.0  21.9% of ALDHbr cells express CD34,
ith lower numbers of ALDHbr cells expressing CD133
mean 27.1  14.1%). Of those ALDHbr cells that were
ositive for CD133 expression, the majority also expressed
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December 4, 2007:2243–8 Identification of EPCs Based on ALDH ActivityD34 (78.4  27.2%). In contrast, these markers are
xpressed in only a very small percentage of cells lacking
LDH activity (percentage of ALDHlow cells expressing
D34 0.18 0.12%, expressing CD133 0.21 0.18%, and
xpressing CD133 and CD34 0.015  0.014%; p  0.0001
or comparison of each ALDHbr subpopulation with
LDHlow cells expressing the same marker[s]). A high
roportion of CD133CD34 cells also exhibit high levels
f ALDH activity (63.5  25.9%). These findings indicate
hat there is substantial, but not complete, overlap of the
LDHbr and CD133CD34 cell populations. Interest-
ngly, ALDHbr cells did not express VEGFR-2 (data not
hown).
Figure 1 EPC Identification Based on ALDH Activity
A discrete group of cells, absent in the diethylaminobenzaldehyde (DEAB) control s
activity and low side-scatter, is identified in the right lower quadrant (right). EPC 
Figure 2 Characterization of ALDHbr Cells
Aldehyde dehydrogenase-bright (ALDHbr) cells were subjected to staining for
expression of select endogenous progenitor cell markers (n  21). The purple
column indicates the percentage of CD133CD34 cells also expressing ele-
vated ALDH activity.CTo assess test precision, we correlated EPC frequencies
etermined in independent samples. Whereas the intrapa-
ient reproducibility of EPC count was high with each
echnique, it was slightly greater for the ALDH assay (r 
.98, n  25 for ALDHbr cells; vs. r  0.94, n  19 for
D133CD34 cells; p  NS for comparison of paired
ifferences).
We also assessed the temporal stability of EPCs by enumer-
ting ALDHbr and CD133CD34 cells in peripheral blood
amples drawn from volunteers at 24-h intervals. Temporal
tability was high for both assays (r  0.87, n  18 for
LDHbr cells; vs. r 0.83, n 18 for CD133CD34 cells;
 NS for comparison of the paired differences).
etermining the endothelial potential of ALDHbr
ells. To determine the potential of ALDHbr cells to
ontribute to vascular repair, we cultured isolated ALDHbr
ells and stained the differentiated cells with endothelial-
pecific markers. Aldehyde dehydrogenase-bright progeny
isplayed robust staining with acetylated low-density li-
oprotein, Ulex lectin, and antibodies to CD31, von Wil-
ebrand factor, and VEGFR-2 (data not shown), demon-
trating that ALDHbr cells readily differentiate into
ndothelial cells. We also compared the capacity of ALDHbr
ells to generate endothelial cells, with EPCs defined using con-
entional markers. When equal numbers of CD133CD34
nd ALDHbr cells were cultured, the numbers of endothelial
ells derived from ALDHbr cells (10 experiments) exceeded
hose obtained from CD133CD34 cells by a factor of 25
mean number of endothelial cells 80.5  2.98 versus 2.3 
.08, respectively).
istribution of EPC numbers. We next determined the
umbers of ALDHbr cells in a prospectively collected series
f 110 patients undergoing cardiac catheterization, while
imultaneously assessing the numbers of MNCs expressing
(left), with high aldehyde dehydrogenase (ALDH)
genous progenitor cell; FITC  fluorescein isothiocyanate.ample
endoD133, CD34, and VEGFR-2. Patient characteristics are
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Identification of EPCs Based on ALDH Activity December 4, 2007:2243–8hown in Table 1. Extent of coronary artery disease was
venly distributed, with about 45% having no significant
AD and 38% having multivessel disease (Table 1).
The numbers of ALDHbr cells were not normally dis-
ributed (D’Agostino and Pearson omnibus normality test:
 0.0001), with a mean of 0.0743  0.067% and median
f 0.0510% (interquartile range [IQR] 0.026 to 0.105) of
NCs displaying high levels of ALDH activity. These
umbers were comparable in magnitude with those ob-
erved for the numbers of CD133CD34 cells (mean
.053  0.043% and median 0.0413% [IQR 0.021 to
.072%]), whereas the numbers of CD34-VEGFR-2
atient Characteristics
Table 1 Patient Characteristics
Factor Mean
Age (yrs) 63.5
Race (Caucasian) 85.1%
Gender (male) 58.2%
Hypertension 73.6%
Hyperlipidemia 68.2%
Diabetes 26.4%
Ongoing tobacco use 25.7%
Prior PCI 18.2%
Prior CABG 11.8%
Extent of CAD
0 vessel 44.9%
1 vessel 16.8%
Multivessel 38.3%
ABG  coronary artery bypass grafting; CAD  coronary artery disease; PCI  percutaneous
oronary intervention.
Figure 3 Correlation Between ALDHbr Cell Numbers and EPCs E
Correlation of aldehyde dehydrogenase-bright (ALDHbr) cells with CD133 cells (A)
growth factor receptor (VEGFR)-2CD34 cells (D). Spearman correlation coefficieells were significantly lower (mean 0.0134  0.027%,
edian 0.0055% [IQR 0.0018 to 0.014%]).
orrelation among EPC assay methodologies. We deter-
ined the association of ALDHbr cells with EPCs identified
ased on expression of CD133, CD34, and VEGFR-2. We
bserved a strong correlation between EPC cell numbers
dentified using the ALDH assay relative to those enumer-
ted based on expression of CD133, CD34, and CD133/
D34 (r  0.25, 0.55, and 0.72, respectively) (Figs. 3A to
C). In contrast, ALDHbr cell numbers failed to correlate
ith the numbers of cells expressing VEGFR-2 or
EGFR-2 and CD34, commonly used markers for EPC
etermination (Fig 3D).
orrelation between ALDH assay findings and patient
ge and CAD severity. To assess the relationship between
hronic vascular injury and ALDHbr cells, we examined the
ssociation between the numbers of ALDHbr cells and
atient age and extent of CAD. As shown in Figure 4, the
umbers of ALDHbr cells varied inversely with patient age (p
0.005). Patients were then divided into those with normal or
inimal disease with no significantly obstructed vessels, single-
essel disease, and advanced multivessel CAD (Fig 4). We
ound a stepwise depletion of ALDHbr cells in patients directly
elated to the extent of CAD.
iscussion
ince the initial description of endogenous circulating
rogenitor cells capable of vascular repair (1), the number of
ublished reports identifying and enumerating these cells
ssing Specific Cell Surface Markers
4 cells (B), CD133CD34 cells (C), and vascular endothelial
shown. EPCs  endogenous progenitor cells; MNCs  mononuclear cells.xpre
, CD3
nts are
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December 4, 2007:2243–8 Identification of EPCs Based on ALDH Activityas dramatically escalated. The use of EPC levels to predict
ardiac risk has been explored in 2 reports demonstrating a
elationship between EPC numbers and subsequent clinical
utcomes (6,7), suggesting that EPC enumeration may be
linically useful for patient risk stratification; however, the
ethodologies required for EPC enumeration require pro-
ciency with cell culture or complex FACS analysis using
ultiple cell surface markers.
Aldehyde dehydrogenase is a key enzymatic activity
xpressed at high levels in progenitor cells. Not only may
LDH activity be a fundamental property of the progenitor
ell phenotype (17), but also selection on the basis of
LDH level may identify cells with greater proliferative and
eparative capacity than progenitor cells selected on the basis
f other markers (12,20). In addition, ALDHbr cells are
apable of differentiation into a variety of phenotypes
15,16). We therefore explored whether ALDH activity
ay serve as a simpler method for identification of EPCs
ith high proliferative and reparative capacity.
We have now demonstrated that ALDHbr cells can be
eliably enumerated using a simple gating strategy with a
ingle fluorescence channel in blood samples from cardiac
atients and that ALDHbr cells transform into endothelial
ells with greater efficiency than other EPCs. These
roperties make the identification of ALDHbr cells a
romising methodology for EPC enumeration in wider
linical contexts.
A substantial portion of ALDHbr cells express CD34 and
D133 markers, and there is strong correlation between the
umbers of ALDHbr cells and the numbers of CD133/
D34 EPCs. We do not find a similar correlation with cells
xpressing CD34VEGFR-2, a combination of markers
ommonly used to identify EPCs. These observations sug-
est that ALDHbr and CD133/CD34 EPCs represent
opulations with substantial overlap, whereas VEGFR-2
ells, including CD34VEGFR-2 EPCs, identify a dis-
inct progenitor cell population. Indeed, evidence suggests
hat different but widely published EPC assays identify cell
ypes which fail to correlate with one another and likely
Figure 4 Correlation of ALDHbr Cell Number and Patient Age an
Aldehyde dehydrogenase-bright (ALDHbr) cells are inversely correlated with patient
coronary artery disease (CAD) (n  110; p value for analysis of variance analysisepresent distinct populations (21,22). Because ALDH fctivity selects for an early progenitor cell phenotype, and
ecause VEGFR-2 is a marker of mature endothelial cells,
he numbers of ALDHbr cells may more accurately reflect
he levels of progenitors capable of long-term self-
eplication (11).
We found a close correlation between the frequency of
LDHbr cells and patients’ age and a stepwise association
ith CAD severity. These observations suggest that
LDHbr cell depletion due to a combination of time and
hronic vascular injury may play an important role in the
oss of vascular reparative capacity preceding the develop-
ent of clinically apparent vascular disease.
The identity of circulating ALDHbr cells and their ability
o contribute to vascular repair is at present not completely
nown; however, several lines of evidence point to the
mportance of these cells in vascular health. First, we have
hown that bone marrow ALDHbr cells are readily cultured
nto cells expressing multiple endothelial markers and show
greater capability for endothelial cell reconstitution than
PCs identified on the basis of CD133 and CD34 expres-
ion, findings recently corroborated by the demonstration
hat the ALDHbr population of bone marrow cells is
arkedly enriched in EPCs (23). Although bone marrow
nd unmobilized circulating progenitors may differ, signif-
cant evidence suggests that ALDHbr cells from a variety of
ources, including marrow, umbilical cord blood, and
obilized blood, is highly concentrated in progenitor
ells of multiple phenotypes, including endothelial cells
13,16,23,24). Second, the correlation of ALDHbr cells
ith CD133CD34 cells and the high levels of cross-
xpression of CD34 and CD133 in the ALDHbr cell
opulation suggest that the ALDH assay identifies a pop-
lation that contains within it a high proportion of cells
reviously identified as EPCs. Finally, the correlation of
LDHbr cells with extent of vascular disease suggests that
LDH activity identifies cells which play an important role
n maintaining vascular integrity.
Whether or not enumeration of ALDHbr cells in patients
ore accurately assesses reparative capacity and risk for
tent of CAD
 110; p  0.01) and extent of
alysis for linear trend). MNCs  mononuclear cells.d Ex
age (n
and anuture cardiovascular events awaits further validation. Ulti-
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Identification of EPCs Based on ALDH Activity December 4, 2007:2243–8ately, the utility of enumerating ALDHbr EPCs will
epend on the association of these cells with clinical
utcomes; however, the simplicity and reliability of this
echnique might allow extension of EPC analysis to a wider
ange of clinical settings, expanding the contexts in which
PC biology might be explored.
onclusions
he measurement of ALDH activity in blood MNCs is a
romising technique for the accurate, reproducible enumera-
ion of circulating EPCs. Aldehyde dehydrogenase-bright
ells can be enumerated with greater simplicity than other
PC types, correlate strongly with some, but not all,
reviously identified EPCs, and are depleted in elderly
atients with coronary disease.
The degree to which enumeration of ALDHbr progenitor
ells reflects reparative capacity, as well as the association of
LDHbr cells with clinical outcomes, will define the use-
ulness of enumerating these cells for risk stratification of
atients as well as further define the value of such cells for
reatment of vascular disease.
cknowledgments
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ells.
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